Get the Stockscreener App
218.04
4.45%
-10.16
After Hours:
217.80
-0.24
-0.11%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $218.04, with a volume of 10.82M.
It is down -4.45% in the last 24 hours and down -5.83% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$228.20
Open:
$223
24h Volume:
10.82M
Relative Volume:
2.00
Market Cap:
$385.18B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
103.76
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
-4.36%
1M Performance:
-5.83%
6M Performance:
+11.76%
1Y Performance:
+6.95%
1-Day Range:
$216.00
$223.87
1-Week Range:
$216.00
$229.65
52-Week Range:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Reversal indicators forming on AbbVie Inc. stockEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Can AbbVie Inc. stock retain market dominance2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
2 Magnificent Dividend Stocks to Buy and Hold Forever - The Motley Fool
State of Michigan Retirement System Buys 1,400 Shares of AbbVie Inc. $ABBV - MarketBeat
Nicholas Company Inc. Cuts Holdings in AbbVie Inc. $ABBV - MarketBeat
Tredje AP fonden Cuts Position in AbbVie Inc. $ABBV - MarketBeat
Triglav Investments D.O.O. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
TIAA Trust National Association Sells 10,325 Shares of AbbVie Inc. $ABBV - MarketBeat
Accuvest Global Advisors Sells 1,690 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Great Lakes Retirement Inc. - MarketBeat
Why AbbVie Stock Flopped on Friday - AOL.com
AbbVie (ABBV) Surpasses Q3 Expectations with Strong Revenue Grow - GuruFocus
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat - MSN
Longbow Finance SA Purchases 37,626 Shares of AbbVie Inc. $ABBV - MarketBeat
Lifeworks Advisors LLC Purchases 1,575 Shares of AbbVie Inc. $ABBV - MarketBeat
Crescent Sterling Ltd. Has $2.90 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Center for Financial Planning Inc. Boosts Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Syverson Strege & Co - MarketBeat
Leeward Financial Partners LLC Buys New Stake in AbbVie Inc. $ABBV - MarketBeat
Haven Private LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
Tax Court allows ordinary deduction of termination fees - Journal of Accountancy
Assetmark Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Long Setup & Low Risk High Win Rate Picks - newser.com
AbbVie Inc. (NYSE:ABBV) to Issue Quarterly Dividend of $1.73 - MarketBeat
AbbVie (ABBV) Margin Compression Reinforces Investor Caution After $14.5 Billion One-Off Loss - Yahoo Finance
AbbVie (NYSE:ABBV) Updates Q4 2025 Earnings Guidance - MarketBeat
AbbVie Inc. stock underperforms Friday when compared to competitors - MSN
AbbVie (NYSE:ABBV) Stock Price Down 4.4%Should You Sell? - MarketBeat
Five Things To Know About AbbVie’s Q3 Sales And Earnings Report - Citeline News & Insights
Looking Into AbbVie Inc's Recent Short Interest - Fidelity
AbbVie (ABBV) Exceeds Q3 Expectations, Raises 2025 Outlook - GuruFocus
AbbVie Inc. (ABBV) Stock Slides 4.45% as Q3 EPS Plunges 88%, Despite 9% Revenue Growth and Strong Immunology Sales - CoinCentral
AbbVie (ABBV) Reports Strong Linzess Sales in Q3 - GuruFocus
Ironwood surges 28% as beneficiary of partner AbbVie's Linzess Q3 sales (IRWD:NASDAQ) - Seeking Alpha
AbbVie raises 2025 EPS guidance and signals strong pipeline milestones into 2026 - MSN
AbbVie (NYSE:ABBV) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised - sharewise.com
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ... - Yahoo Finance
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira Challenges - GuruFocus
AbbVie raises full-year forecast, Newell Brands stock plunges - Yahoo Finance
AbbVie (ABBV) Boosts Quarterly Dividend by 5.5% - GuruFocus
AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025 - MarketScreener
Research Alert: CFRA Keeps Buy Rating On Shares Of Abbvie Inc. - 富途牛牛
Why AbbVie (ABBV) Shares Are Falling Today - Yahoo Finance
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - sharewise.com
AbbVie Inc (ABBV) Q3 Earnings: Adjusted EPS of $1.86 Surpasses E - GuruFocus
AbbVie says Trump pressing for larger Medicare drug price cuts - Reuters
AbbVie near 1-month low after earnings report 📉 - XTB.com
AbbVie raises outlook on strong sales of mainstay drugs - Crain's Chicago Business
AbbVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):